Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00498797 | E3-Hormone Refractory Prostrate Cancer Taxotere Combination | PHASE2 | COMPLETED | 86 | — | — | Dec 1, 2005 | Sep 1, 2008 | Oct 7, 2016 | 11 | Brazil, Germany +3 |
Prostate Specific Antigen (PSA) response was defined as a reduction of at least 50% from baseline at any assessment, confirmed by a second assessment 2-4 weeks after the initial response
| Name | Type | Description |
|---|---|---|
| Zactima (vandetanib) | DRUG | - |
| Docetaxel | DRUG | - |
| Prednisolone | DRUG | - |
Inclusion Criteria: * Metastatic hormone refractory prostate cancer defined as those patients with evidence of progression of disease in spite of castrate levels of testosterone indicated by rising levels of PSA * No previous chemotherapy although those patients that have received estramustine can ...